Cellectar Biosciences Reports 79.2% Major Response Rate For Iopofosine I 131 In Phase 2 Subset Of Waldenström Macroglobulinemia Patients After BTK Inhibitors

Loading news article.

Cellectar Biosciences Reports 79.2% Major Response Rate For Iopofosine I 131 In Phase 2 Subset Of Waldenström Macroglobulinemia Patients After BTK Inhibitors | WAPE

Cellectar Biosciences Reports 79.2% Major Response Rate For Iopofosine I 131 In Phase 2 Subset Of Waldenström Macroglobulinemia Patients After BTK Inhibitors

Article summary

Related companies

Comments —